Optimal Enrollment in Late-Stage New Drug Development with Learning of Drug’s Efficacy for Group-Sequential Clinical Trials

Zhili Tian (), Gordon B. Hazen () and Hong Li ()
Additional contact information
Zhili Tian: Department of General Business, Marketing, and Supply Chain Management, Marilyn Davies College of Business, University of Houston, Houston, Texas 77002
Gordon B. Hazen: Department of Industrial Engineering and Management Sciences, Northwestern University, Evanston, Illinois 60208
Hong Li: Department of Public Health Sciences, School of Medicine, University of California, Davis, California 95616

Manufacturing & Service Operations Management, 2023, vol. 25, issue 1, 88-107

Abstract: Problem definition : The cost for developing a new drug ranged from $1 billion to more than $2 billion between 2010 and 2019. In addition to high development costs, the efficacy of the candidate drug, patient enrollment, the market exclusivity period (MEP), and the planning horizon are uncertain. Moreover, slow enrollment leads to increased costs, canceled clinical trials, and lost potential revenue. Many firms, hoping to detect efficacy versus futility of the candidate drug early to save development costs, plan interim analyses of patient-response data in their clinical trials. Academic/practical relevance : The problem for optimizing patient-enrollment rates has an uncertain planning horizon. We developed a continuous-time dynamic programming (DP) model with learning of a drug’s efficacy and MEP to assist firms in developing optimal enrollment policies in their clinical trials. We also established the optimality equation for this DP model. Through a clinical trial for testing a cancer drug developed by a leading pharmaceutical firm, we demonstrate that our DP model can help firms effectively manage their trials with a sizable profit gain (as large as $270 million per drug). Firms can also use our model in simulation to select their trial design parameters (e.g., the sample sizes of interim analyses). Methodology : We update a drug’s efficacy by Bayes’ rules. Using the stochastic order and the likelihood-ratio order of distribution functions, we prove the monotonic properties of the value function and an optimal policy. Results : We established that the value of the drug-development project increases as the average response from patients using the candidate drug increases. For drugs having low annual revenue or a strong market brand or treating rare diseases, we also established that the optimal enrollment policy is monotonic in the average patient response. Moreover, the optimal enrollment rate increases as the variance of the MEP decreases. Managerial implications : Firms can use the properties of the value function to select late-stage clinical trials for their drug-development project portfolios. Firms can also use our optimal policy to guide patient recruitment in their clinical trials considering competition from other drugs in the marketplace.

Keywords: clinical trial management; learning of drug efficacy; new drug development management; optimal enrollment rate; R&D project management; market exclusivity period (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
http://dx.doi.org/10.1287/msom.2022.1162 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:ormsom:v:25:y:2023:i:1:p:88-107

Access Statistics for this article

More articles in Manufacturing & Service Operations Management from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher ().